Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bupropion/trazodone

Next Previous
Drug Profile

Bupropion/trazodone

Alternative Names: Lorexys; Orexa; S1P-104; S1P-205; SIP-104; Trazodone/bupropion

Latest Information Update: 27 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator S1 Pharmaceuticals
  • Developer S1 Biopharma
  • Class Erectile dysfunction therapies; Piperazines; Propiophenones; Pyridones; Small molecules
  • Mechanism of Action 5-HT2C serotonin receptor antagonists; Adrenergic uptake inhibitors; Alpha adrenergic receptor agonists; Dopamine uptake inhibitors; Serotonin 5-HT2A receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Sexual function disorders

Highest Development Phases

  • Phase II Erectile dysfunction; Female sexual dysfunction
  • No development reported Male sexual dysfunction

Most Recent Events

  • 27 Sep 2021 Bupropion/trazodone is still in phase IIb trial for Female sexual dysfunction in USA (S1 Biopharma pipeline, September 2021)
  • 27 Sep 2021 Phase-II clinical trials in Erectile dysfunction (PO) (S1 Biopharma pipeline, September 2021)
  • 20 Dec 2018 S1 Biopharma has patent protection for Bupropion/trazodone (Lorexys™) in Asia and Europe

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top